Under Pressure: Assessing Novel Treatment Options for Glaucoma

Login
Register
My Saved

My Account
Cart ()
Log Out
My Saved

Topics
Editorial Board
Educational Tools

Clinical Science/Basic Research
Diagnostic Testing & Monitoring
Pharmacotherapy
Laser Therapy
Compliance
Clinical Trials
Practice Management
Surgery

Editorial Board
Educational Tools

CME Information
Pretest
Assessing Novel Treatment Options for Glaucoma
Low Perfusion Pressure in Glaucoma
Educational Tools
Posttest
Evaluation

Home
Pharmacotherapy
Under Pressure: Assessing Novel Treatment Options for Glaucoma

This activity is expired and is no longer available for CME credit.

CME Information
Pretest
Assessing Novel Treatment Options for Glaucoma
Low Perfusion Pressure in Glaucoma
Educational Tools
Posttest
Evaluation

This activity is supported by an educational grant from Bausch + Lomb.

Activity Contents

CME Information
Pretest
Assessing Novel Treatment Options for Glaucoma
Low Perfusion Pressure in Glaucoma
Educational Tools
Posttest
Evaluation

CME Information

LECTURECME

Under Pressure: Assessing Novel Treatment Options for Glaucoma

Author(s)/Faculty: Thomas W. Samuelson, MD; John R Samples, MD
Release Date: 9/1/2016	Expiration Date: 8/31/2018
Credit Type: CME	Number of Credits: 0
Content Type: Lecture	Provider:
Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will comprise the recent evidence about low perfusion pressure and its association with glaucoma damage and progression.

These continuing medical education activities are provided by

New to English? Translate here.

These continuing medical education activities are provided by

New to English? Translate here.

Overview

Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.

CME Information

Providership and Support

Provider Statement: This continuing medical education activity is provided by .

Support Statement: This activity is supported by an educational grant from Bausch + Lomb.

Target Audience and Learning Objective

Target Audience: The intended audience for the activities is comprehensive ophthalmologists and other health care professionals involved in the treatment of patients with glaucoma.

Learning Objectives: Upon successful completion of this educational activity, participants should be better able to:

Assess recent evidence about low perfusion pressure and its association with glaucoma damage and progression.
Evaluate established and new therapeutic agents for the optimal treatment of patients with glaucoma, based on the recent clinical evidence for their safety and efficacy.

Faculty and Disclosures

Activity Chair:
Thomas W. Samuelson, MD
Attending Surgeon
Minnesota Eye Consultants, PA
Adjunct Associate Professor
University of Minnesota
Minneapolis, MN

Faculty:
John R. Samples, MD
Clinical Professor, Rocky Vista University
Parker CO
Director, Western Glaucoma Foundation
Olympia, WA and Portland, OR

External Reviewer:
Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty Members report the following relationship(s) which are accurate at the time of original content release (September 1, 2016):
Thomas W. Samuelson, MD
Consulting Fees: Abbott Medical Optics; AcuMems; Aerie; Alcon Laboratories, Inc.; Allergan, Inc.; Aquesys; Endo Optiks; Glaukos Corporation; Inotek; Ivantis; Merck; Ono Pharma USA; QLT; Santen; SLACK Inc.; Transcend Medical
Ownership Interests: (Stock Options): Aquesys; Glaukos Corporation; Ivantis

John R. Samples, MD
Royalty: Springer (From 3 books), Kugler
Intellectual Property/Patent Details: Allergan, Aquasys, Cyogenetix, ReFocus
Consulting Fees: Aerie, Alcon, Copernicus Group, Roche, Transend, Western IRB
Speakers Bureau: Alcon, Roche
Contracted Research: National Eye Institute
Ownership Interest: Allergan, Amgen, Aquasys, Eyegenetix, Gilead

External Reviewer reports the following relationship(s):
Ronald A. Codario MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose

Vindico Medical Education staff report the following relationship(s):
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Credit Information

Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material was originally approved for 1 year from the date of original release, September 1, 2016 through August 31, 2017. It has since been recertified for an additional year and will now expire on August 31, 2018.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentations, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright and Questions

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at cme@vindicoCME.com